Two Analysts Don't See Celgene's Weak Trial Results As A Huge Setback
July 09, 2014 at 12:37 PM EDT
Shares of Celgene (NASDAQ: CELG) have been volatile since the company announcedweak Phase III trial resultsfor ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.